NCT04548869View on ClinicalTrials.gov

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

December 16, 2022

Study Completion Date

May 12, 2023

Conditions
Cold UrticariaCold Contact UrticariaSymptomatic DermographismSymptomatic DermatographismCholinergic Urticaria
Interventions
DRUG

CDX-0159

Administered intravenously

Trial Locations (1)

10117

Charite University, Berlin

Sponsors
All Listed Sponsors
lead

Celldex Therapeutics

INDUSTRY

NCT04548869 - A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria | Biotech Hunter | Biotech Hunter